Skip to main content
. Author manuscript; available in PMC: 2020 Apr 3.
Published in final edited form as: J Am Stat Assoc. 2019 Apr 3;114(527):1038–1049. doi: 10.1080/01621459.2018.1529594

Figure 1:

Figure 1:

Results from the TMLE analysis of the RV144 trial. Top: Cumulative incidence in vaccine and control groups of HIV-1 infections matched (left) and mismatched (right) to the vaccine at AA 169. Bottom left: Vaccine efficacy against matched (triangle) and mismatched (circle) infections. Bottom right: Vaccine sieve effect with 95% confidence intervals.